Eli Lilly is just weeks ... of GLP-1 and GIP agonist tirzepatide. Great Britain will be the first major market to be supplied with the drug in the multi-shot pen injector format.

US Senators are concerned that Pfizer and Eli Lilly's recent forays into direct ... to induce specific actions of the prescribing pen." Both Lilly and Pfizer claim their programmes tap into ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Following the FDA’s reaffirmation, 503B compounding pharmacies have until March 19 to stop selling compounded tirzepatide. In its motion filed on New Year’s Day, Eli Lilly stated it seeks to ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. ‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

(Image Credits: Pixabay) It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. Zepbound’s superior efficacy and ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly's competition with Novo Nordisk continues. “From the start, Zepbound emerged as the primary new ...